SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?

Gary C W Chan; Sydney C W Tang

doi:10.1016/j.kint.2017.07.008

SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?

Kidney Int. 2018 Jan;93(1):22-24. doi: 10.1016/j.kint.2017.07.008.

Authors

Gary C W Chan¹, Sydney C W Tang²

Affiliations

¹ Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
² Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong. Electronic address: [email protected].

PMID: 29291819
DOI: 10.1016/j.kint.2017.07.008

Abstract

Sodium glucose cotransporter 2 inhibitors are a relatively new adjunctive treatment option for type 2 diabetes (T2D). Extraglycemic benefits of sodium glucose cotransporter 2 inhibition include weight and blood pressure reduction. Cherney et al. now demonstrate that these extraglycemic properties of empagliflozin are preserved despite reduced urinary glucose excretion in advancing chronic kidney disease. Limited therapeutic options for patients with type 2 diabetes in the latter stages of chronic kidney disease make empagliflozin an attractive therapeutic agent with additional cardiovascular benefits.

Publication types

Comment

MeSH terms

Benzhydryl Compounds
Blood Glucose
Diabetes Mellitus, Type 2*
Glucosides
Humans
Hypoglycemic Agents
Sodium-Glucose Transporter 2*

Substances

Benzhydryl Compounds
Blood Glucose
Glucosides
Hypoglycemic Agents
Sodium-Glucose Transporter 2
empagliflozin